Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.


Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.

Product support and resources for your patients

Access Card Access Card

For eligible commercially insured patients:

Aimovig® free for up to 12 doses* or $5 copay per month

Program Details:

With the Aimovig Ally Access Card, an eligible commercially insured patient can receive one of the following two offers:

*If the patient’s health plan does not cover Aimovig® (erenumab-aooe) or requires a prior authorization, the patient can receive Aimovig® free for up to 12 doses over 24 months from the date of the first prescription filled under the Bridge to Commercial Coverage Offer. See full Terms and Conditions below.

If Aimovig® is approved by the patient’s health plan, a patient pays a $5 copay per month, up to a maximum benefit of $2700 annually. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig®. Patient is responsible for costs above the annual maximum. See full Terms and Conditions below.

Download and provide commercial
patients with our
Aimovig Ally Access
Card Brochure
so they can enroll today

PA Support Through CoverMyMeds

  • Aimovig® is a sponsored product through CoverMyMeds, which provides payer-specific prior authorization (PA) forms, coverage determinations, and monitoring of your submissions.

Have More Questions?

  • Simply call 833-AIMOVIG (833-246-6844), Monday–Friday, 8:00 am–8:00 pm ET.

Amgen Safety Net Foundation is an independent, nonprofit patient assistance program that provides Aimovig® at no cost to qualifying patients who have a financial need and who are uninsured or have insurance that excludes Aimovig®. Click here to learn more.

Terms and Conditions for Bridge to Commercial Coverage Offer (“Bridge Offer”) – Aimovig® free for up to 12 doses over 24 months (whichever occurs first) from the first prescription filled under the Bridge Offer: Patient must be prescribed Aimovig® and have previously failed another preventive migraine treatment. Available if patient is commercially insured and 18 years or older. This offer is not valid if patient is uninsured or receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, the Retiree Drug Subsidy Program, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE or where prohibited by law. Cash Discount Cards and other noninsurance plans are not valid as primary under this offer. If at any time patient begins receiving coverage under any such federal-, state-, or government-funded healthcare program, patient will no longer be able to use this offer and patient must call 833-AIMOVIG to stop participation. By participating in this offer, patient acknowledges intent to pursue insurance coverage for Aimovig® with their healthcare provider. Ongoing eligibility requires that patient has (i) a prior authorization or medical exception denied within 90 days of first use of offer, and (ii) an appeal of the prior authorization or medical exception denied within 180 days of first use of offer. Once insurance approval is obtained, patient is no longer eligible for this offer. No purchase necessary. This is not health insurance. Participation is not a guarantee of insurance coverage. This offer is not renewable. Valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. This offer is subject to change or discontinuation without notice.

Terms and Conditions for Copay Offer: Pay a $5 copay per month, up to a maximum benefit of $2700 annually. Patient must be prescribed Aimovig®. Available if patient is commercially insured and 18 years or older. This offer is not valid if patient is uninsured or receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, the Retiree Drug Subsidy Program, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE or where prohibited by law. Cash Discount Cards and other noninsurance plans are not valid as primary under this offer. If at any time patient begins receiving coverage under any such federal-, state-, or government-funded healthcare program, patient will no longer be able to use this offer and patient must call 833-AIMOVIG to stop participation. Patient may not seek reimbursement for value received from this offer from any third-party payers, including flexible spending accounts or healthcare savings accounts. This is not health insurance. Participation is not a guarantee of insurance coverage. Valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. This offer is subject to change or discontinuation without notice. If you become aware that your health plan or pharmacy benefit manager does not allow the use of manufacturer copay support as part of your health plan design, you agree to comply with your obligations, if any, to disclose your use of the card to your insurer. This offer is ongoing and in order to remain eligible, patient must re-enroll every 12 months by visiting www.aimovigaccesscard.com/ or by calling 833-AIMOVIG (833-246-6844).

PLEASE NOTE: Every pharmacy has different systems and procedures. For any questions, the pharmacist or pharmacy tech can call the Change Healthcare Pharmacy Help Desk at 1-800-422-5604.



Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.